Introduction {#sec1}
============

Gastric cancer has become a major public health problem. In 2012, an estimated 951600 new gastric cancer cases and 723100 gastric cancer deaths occurred globally \[[@B1]\]. The highest gastric cancer incidence and mortality rates were found in East Asia, with approximately 679100 new cancer cases and 498000 cancer deaths reported in 2015 in China \[[@B2]\]. Carcinogenesis is a multi-step complex disease resulting from both environmental and genetic factors \[[@B3]\]. In Asia, the prevalence of *Helicobacter pylori* (*H. pylori*) is found as an important etiological factor for the development of gastric cancer \[[@B4]\]. In addition, previous studies showed that the potential environmental factors associated with gastric cancer might include tobacco smoking, alcohol use, dietary habits, unrefined vegetable oil, intake of water and daily consumption of meat-broth \[[@B5],[@B6]\]. Furthermore, genetic factors have been also found to play an important role in the development of gastric cancer. In a two-stage genome-wide association study (GWAS) conducted in the Korean and Japanese populations, the *prostate stem cell antigen* (*PSCA*) gene polymorphisms were reported to be associated with an increased risk of gastric cancer \[[@B7]\].

The *PSCA* gene is located on chromosome 8q24.2, encoding a 123-amino acid glycoprotein, a cell surface antigen \[[@B8]\]. *PSCA* gene was identified as a prostate-specific antigen and to be associated with cell adhesion, proliferation and patient survival \[[@B9],[@B10]\]. PSCA was reported to be overexpressed in many types of human cancers, and since it has restricted expression in normal tissues \[[@B11]\]. The *PSCA* gene polymorphisms were found to be associated with higher PSCA expression in cancer patients, such as rs2294008 \[[@B12]\]. Rs2294008 C \> T and rs2976392 G \> A polymorphism, the most widely studied polymorphisms in the *PSCA* gene, have demonstrated to be associated with an increased risk of gastric cancer \[[@B7]\]. However, rs2976392 was not found to be associated with the risk of cardia gastric cancer and rs2294008 was not associated with gastric cancer in the subsequent replication studies \[[@B13],[@B14]\].

In view of this, we carried out a case--control study to investigate the association between *PSCA* gene rs2294008 C \> T and rs2976392 G \> A polymorphism and the risk of gastric cancer in the Chinese population.

Materials and methods {#sec2}
=====================

Study population {#sec2-1}
----------------

A total of 549 genetically unrelated cases with gastric cancer and 592 healthy controls of Chinese origin were included in the current study. All the patients were newly diagnosed and histopathologically confirmed primary gastric cancer, and recruited from the First Affiliated Hospital of Nanchang University from January 2010 to July 2014. In addition, age and gender-matched cancer-free Chinese controls were randomly recruited from the same region. Demographic characteristics and lifestyle habits of all subjects were collected. The current study was approved by the Institutional Review Board of First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, and carried out in accordance with the World Medical Association Declaration of Helsinki. All the participants have provided the written informed consent, accompanying with a donation of approximately 5 ml blood.

Genotyping {#sec2-2}
----------

Genomic DNA was extracted using the TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) according to the manufacturer's instructions. TaqMan real-time polymerase chain reaction (PCR) was applied to acquire the genotypes by using the ABI QuantStudio DX system \[[@B15],[@B16]\]. Briefly, the final volume was 10 μl and consisted of 5 μl TaqMan universal PCR Master Mix, 0.5 μl Primer/probe mix and 10 ng genomic DNA. The PCR program had an initial denaturation step at 95°C for 10 min and 40 cycles at 94°C for 15 s and 60°C for 45 s. Allele frequencies were analyzed by using ABI SDS software. For quality control, genotyping was repeated on a random 10% of the samples, and 100% concordance rate was observed for the results.

Statistical analysis {#sec2-3}
--------------------

The Chi square test was applied to evaluate the differences in the distributions of genotypic frequencies and demographic variables among all the cases and controls. The odds ratios (ORs) and 95% confidence intervals (CIs), calculated by logistic regression models with adjustment for age, sex, smoking and drinking status, were used to assess the associations between the *PSCA* polymorphisms and the gastric cancer risk. The combined effect of the two *PSCA* polymorphisms and the gastric cancer risk was also calculated in logistic regression models. Moreover, we conducted stratification analyses by age, sex, smoking/drinking status and tumor site. All the statistics were performed by the SAS software (version 9.4; SAS Institute, Cary, NC). All the *P*-values were two sided, and *P*\<0.05 was considered as statistically significant.

Results {#sec3}
=======

A total of 549 gastric cancer patients and 592 healthy controls were included in the present study. Subjects were well matched by age and sex. There were no significant differences between the cases and the controls for age (59.22 ± 10.94 vs. 58.45 ± 11.74, *P*=0.421) and sex (*P*=0.485). However, the controls were more likely to be smokers (*P*\<0.001) and drinkers (*P*\<0.001) compared with the cases of gastric cancer patients. Therefore, age, sex, smoking and drinking status were further adjusted for multivariate analysis.

The *PSCA* gene rs2294008 C \> T and rs2976392 G \> A genotype frequencies and their associations with the risk of gastric cancer in the Chinese population are shown in [Table 1](#T1){ref-type="table"}. For rs2294008 C \> T, T is the risk allele. Additive model is a nonparametric regression method, is the trend of CC-CT-TT, dominant model is for CT+TT vs. CC and recessive model is for TT vs. CT+CC. For rs2976392 G \> A, A is the risk allele. Additive model is the trend of GG-GA-AA, dominant model is for GA+AA vs. GG and recessive model is for AA vs. GA+GG. The *PSCA* gene rs2294008 C \> T was found to significantly increase the risk of gastric cancer (CT vs. CC, OR = 1.55, 95% CI = 1.20--1.99, *P*\<0.001 and CT+TT vs. CC, OR = 1.38, 95% CI = 1.09--1.74, *P*=0.008). A similar association with gastric cancer risk was also found for the *PSCA* gene rs2976392 G \> A (GA vs. GG, OR = 1.61, 95% CI = 1.25--2.07, *P*\<0.001 and GA+AA vs. GG, OR = 1.52, 95% CI = 1.20--1.92, *P*\<0.001). When these two polymorphisms were combined, subjects with more than one risk genotypes have a significantly increased risk of gastric cancer (OR = 1.38, 95% CI = 1.09--1.75, *P*=0.008), compared with those without any risk genotypes.

###### Association of *PSCA* genotypes with gastric cancer

  Genotype                            Cases (*n*=549)   Controls (*n*=592)   *P*[^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)       *P*       Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P*[^2^](#T1TFN2){ref-type="table-fn"}
  ----------------------------------- ----------------- -------------------- ---------------------------------------- ----------------------- --------- --------------------------------------------------------- ----------------------------------------
  rs2294008 (HWE \< 0.001)                                                                                                                                                                                        
  CC                                  269 (49.00)       337 (56.93)                                                   1.00                              1.00                                                      
  CT                                  236 (42.99)       191 (32.26)                                                   **1.55 (1.21--1.99)**   \<0.001   **1.55 (1.20--1.99)**                                     \<0.001
  TT                                  44 (8.01)         64 (10.81)                                                    0.86 (0.57--1.31)       0.482     0.86 (0.56--1.31)                                         0.482
  Additive                                                                   \<0.001                                  1.13 (0.94--1.34)       0.190     1.13 (0.94--1.35)                                         0.194
  Dominant                            280 (51.00)       255 (43.07)          0.007                                    **1.38 (1.09--1.74)**   0.007     **1.38 (1.09--1.74)**                                     0.008
  Recessive                           505 (91.99)       528 (89.19)          0.107                                    0.72 (0.48--1.08)       0.108     0.72 (0.48--1.08)                                         0.109
  rs2976392 (HWE = 0.001)                                                                                                                                                                                         
  GG                                  267 (48.63)       349 (58.95)                                                   1.00                              1.00                                                      
  GA                                  236 (42.99)       192 (32.43)                                                   **1.61 (1.25--2.06)**   \<0.001   **1.61 (1.25--2.07)**                                     \<0.001
  AA                                  46 (8.38)         51 (8.61)                                                     1.18 (0.77--1.81)       0.452     1.18 (0.76--1.82)                                         0.456
  Additive                                                                   \<0.001                                  **1.27 (1.06--1.53)**   0.009     **1.27 (1.06--1.53)**                                     0.009
  Dominant                            282 (51.37)       243 (41.05)          \<0.001                                  **1.52 (1.20--1.92)**   \<0.001   **1.52 (1.20--1.92)**                                     \<0.001
  Recessive                           503 (91.62)       541 (91.39)          0.886                                    0.97 (0.64--1.47)       0.887     0.97 (0.64--1.48)                                         0.884
  Combined effect of risk genotypes                                                                                                                                                                               
  0                                   267 (48.63)       335 (56.59)          0.007                                    1.00                              1.00                                                      
  1--2                                282 (51.37)       257 (43.41)                                                   **1.38 (1.09--1.74)**   0.007     **1.38 (1.09--1.75)**                                     0.008

Abbreviation: HWE, Hardy--Weinberg equilibrium.

Chi square test for genotype distributions between cases and controls.

Adjusted for age, sex, smoking and drinking status.

The risk genotypes were rs2294008 TT and rs2976392 AA.

Stratification analysis was further performed to evaluate the association between the two polymorphisms and gastric cancer risk under the dominant genetic model ([Table 2](#T2){ref-type="table"}). We found that subjects carrying rs2294008 CT/TT genotypes were associated with an increased risk of gastric cancer in the youngers (OR = 1.40, 95% CI = 1.00--1.94, *P*=0.049), the males (OR = 1.39, 95% CI = 1.06--1.84, *P*=0.019), the never-smoker (OR = 1.43, 95% CI = 1.03--1.97, *P*=0.031), the ever-drinker (OR = 1.60, 95% CI = 1.01--2.55, *P*=0.048), and the subjects with non-cardia tumor site (OR = 1.43, 95% CI = 1.11--1.85, *P*=0.006). For the *PSCA* gene rs2976392 G \> A, we also found significantly increased associations in the subgroups of ≤59 years old (OR = 1.53, 95% CI = 1.10--2.13, *P*=0.012), \>59 years old (OR = 1.48, 95% CI = 1.05--2.08, *P*=0.024), males (OR = 1.56, 95% CI = 1.18--2.06, *P*=0.002), never and ever smoking (OR = 1.52, 95% CI = 1.10--2.10, *P*=0.012 and OR = 1.56, 95% CI = 1.10--2.23, *P*=0.013), never and ever drinking (OR = 1.43, 95% CI = 1.09--1.89, *P*=0.010 and OR = 1.81, 95% CI = 1.13--2.8823, *P*=0.013), and non-cardia tumor site (OR = 1.55, 95% CI = 1.20--2.01, *P*=0.001). Furthermore, the combined effects of these two polymorphisms on increased risk of gastric cancer were also indicated in the younger subjects, the males, the never-smoker, the ever-drinker and the subjects with non-cardia tumor site.

###### Stratification analysis for the association between *PSCA* polymorphisms and gastric cancer risk

  Variables         rs2294008 (cases/controls)   Adjusted OR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   rs2976392 (cases/controls)   Adjusted OR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   Combined effect of risk genotypes (cases/controls)   Adjusted OR (95% CI)[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}                                     
  ----------------- ---------------------------- --------------------------------------------------------- ---------------------------------------- ---------------------------- --------------------------------------------------------- ---------------------------------------- ---------------------------------------------------- --------------------------------------------------------- ---------------------------------------- --------- ----------------------- -------
  Age                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ≤59               132/137                      139/130                                                   **1.40 (1.00--1.94)**                    0.049                        131/177                                                   140/124                                  **1.53 (1.10--2.13)**                                0.012                                                     131/170                                  140/131   **1.39 (1.00--1.94)**   0.049
  \>59              137/166                      141/125                                                   1.33 (0.95--1.86)                        0.103                        136/172                                                   142/119                                  **1.48 (1.05--2.08)**                                0.024                                                     136/165                                  142/126   1.34 (0.95--1.97)       0.094
  Sex                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Females           70/81                        81/71                                                     1.37 (0.86**--**2.16)                    0.184                        70/83                                                     81/69                                    1.45 (0.91**--**2.29)                                0.116                                                     70/81                                    81/71     1.37 (0.86**--**2.16)   0.184
  Males             199/256                      199/184                                                   **1.39 (1.06--1.84)**                    0.019                        197/266                                                   201/174                                  **1.56 (1.18--2.06)**                                0.002                                                     197/254                                  201/186   **1.40 (1.06--1.84)**   0.018
  Smoking status                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Never             162/159                      174/122                                                   **1.43 (1.03--1.97)**                    0.031                        162/163                                                   174/118                                  **1.52 (1.10--2.10)**                                0.012                                                     162/158                                  174/123   **1.41 (1.02--1.94)**   0.039
  Ever              107/178                      106/133                                                   1.35 (0.95**--**1.92)                    0.095                        105/186                                                   108/125                                  **1.56 (1.10--2.23)**                                0.013                                                     105/177                                  108/134   1.38 (0.97**--**1.97)   0.072
  Drinking status                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Never             213/227                      218/178                                                   1.31 (0.99**--**1.72)                    0.055                        212/235                                                   219/170                                  **1.43 (1.09--1.89)**                                0.010                                                     212/225                                  219/180   1.30 (0.99**--**1.71)   0.064
  Ever              56/110                       62/77                                                     **1.60 (1.01--2.55)**                    0.048                        55/114                                                    63/73                                    **1.81 (1.13--2.88)**                                0.013                                                     55/110                                   63/73     **1.65 (1.04--2.64)**   0.034
  Tumor site                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Cardia            75/337                       66/255                                                    1.20 (0.83**--**1.76)                    0.337                        73/349                                                    68/243                                   1.39 (0.95**--**2.03)                                0.087                                                     73/335                                   68/257    1.26 (0.86**--**1.84)   0.230
  Non-cardia        194/337                      214/255                                                   **1.43 (1.11--1.85)**                    0.006                        194/349                                                   214/243                                  **1.55 (1.20--2.01)**                                0.001                                                     194/335                                  214/257   **1.41 (1.09--1.82)**   0.008

Adjusted for age, sex, smoking and drinking status.

The risk genotypes were rs2294008 TT and rs2976392 AA.

Discussion {#sec4}
==========

In this hospital-based case--control study, we investigated the association of the two *PSCA* gene rs2294008 C \> T and rs2976392 G \> A polymorphisms with the risk of gastric cancer in 549 patients and 592 healthy controls of Chinese origin. We found that the *PSCA* gene rs2294008 CT/TT and rs2976392 GA/AA genotypes significantly increased the risk of gastric cancer in the Chinese population, especially in the younger subjects, the males, the never-smokers, the ever-drinkers and the subjects with non-cardia tumor site. These findings suggested that the two *PSCA* gene rs2294008 C \> T and rs2976392 G \> A polymorphisms were associated with the gastric cancer risk and may contribute to the gastric cancer susceptibility.

*PSCA* gene is a member of LY-6/Thy-1 family of cell surface antigens, and PSCA protein was reported as a cell surface marker having an important role in cell adhesion, proliferation and patient survival \[[@B8]\]. Abnormal expression of PSCA has been observed in many types of human cancers, including prostate, pancreas, bladder, ovarian, esophagus, gallbladder and gastric cancer \[[@B7],[@B8],[@B17]\]. Therefore, it is necessary to investigate the role of PSCA polymorphisms in the etiology of gastric cancer. Previously, GWASs had indicated that the two *PSCA* gene rs2294008 C \> T and rs2976392 G \> A polymorphisms were significantly associated with the risk of gastric cancer in the Chinese, Japanese, Korean and Caucasian populations \[[@B7],[@B14],[@B20]\]. However, the results remain controversial. For example, Ou et al. \[[@B21]\] found *PSCA* gene rs2294008 C \> T polymorphism significantly associated with gastric cancer risk in Chinese populations, but such finding was not replicated in Lu et al. \[[@B14]\]. To further confirm the association, we conducted a replication study and found that the *PSCA* rs2294008 contributed to the increased gastric cancer susceptibility (CT vs. CC, OR = 1.55, 95% CI = 1.20--1.99, *P*\<0.001 and CT+TT vs. CC, OR = 1.38, 95% CI = 1.09--1.74, *P*=0.008). The mechanism of *PSCA* rs2294008 associated with cancer risk remains unclear. However, *in vitro* experiments have noted that the variant might reduce the transcriptional activity of an upstream fragment of this gene \[[@B22]\]. Meanwhile, we confirmed the potential association between rs2294008 and mRNA expression doing the expression quantitative trait loci (eQTL) analysis with GTEx portal website (<http://www.gtexportal.org/home/>) ([Figure 1](#F1){ref-type="fig"}). Whereas, for *PSCA* rs2976392, we also established that *PSCA* rs2976392 polymorphism is significantly associated with an increased risk of gastric cancer in the Chinese population. The *PSCA* rs2976392 polymorphism was also reported to relate to the increased risk of gastric cancer in some previous studies \[[@B16],[@B23]\], but in some other studies including meta-analyses no such association was suggested \[[@B24]\]. This discrepancy should be due to the GWASs which had the large number and dominated the result of the pooled analyses in the meta-analysis \[[@B11]\]. Nevertheless, the molecular mechanism of *PSCA* rs2976392 was still unclear; its strong linkage disequilibrium with *PSCA* rs2294008 can explain the positive association in the previous case--control studies. Therefore, we also conducted linkage disequilibrium analysis for *PSCA* gene rs2294008 and rs2976392 in Han Chinese population consisting of CHB (Han Chinese in Beijing, China) and CHS (Southern Han Chinese) subjects (<https://ldlink.nci.nih.gov/?tab=ldmatrix>). As shown in [Figure 2](#F2){ref-type="fig"}, there was significant linkage disequilibrium between *PSCA* rs2294008 and rs2976392 (*R^2^* = 0.988). In addition, we also examined the potential relationship between rs2976392 and the expression of mRNA, and found that their relationship was the same as that between rs2294008 and the expression of mRNA ([Figure 1](#F1){ref-type="fig"}). In our current study, the combined effects of these two polymorphisms on the increased risk of gastric cancer were also found. It is similar to the effects of each individual genotype, mainly because of high linkage disequilibrium between *PSCA* rs2294008 and rs2976392.

![Effect of *PSCA* gene rs2294008 and mRNA expression based on the GTEx portal website\
Their relationship was the same as that between rs2976392 and mRNA expression.](bsr-39-bsr20181025-g1){#F1}

![Linkage disequilibrium analysis for *PSCA* gene rs2294008 and rs2976392 in Han Chinese population consisting of CHB and CHS subjects](bsr-39-bsr20181025-g2){#F2}

Several limitations should be acknowledged in the present study. First, because of the inherent selection bias and information bias, we further conducted multivariate logistic regression analysis on age, sex, smoking and drinking status. Second, we only did the stratification analyses of age, sex, smoking, drinking status and tumor site, however, other gastric cancer risk factors, such as *H. pylori* infection, diet and occupation exposure, might also contribute to the etiological roles in gastric carcinogenesis. Third, we only investigated two polymorphisms in the *PSCA* gene. More potential polymorphisms are needed to be included. Finally, our findings gained from only the Chinese population and cannot be extrapolated to other populations.

In summary, our findings verified that the two *PSCA* gene rs2294008 C \> T and rs2976392 G \> A polymorphisms were significantly associated with an increased risk of gastric cancer in the Chinese population. Well-designed functional studies are to be warranted to confirm these findings.
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